FIRST RESULTS OF THE DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED MULTICENTER CLINICAL TRIAL OF DIM-BASED THERAPY DESIGNED AS PERSONALIZED APPROACH TO REVERSE PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) ArticlePaltsev M., Kiselev V., Drukh V., Muyzhnek E., Kuznetsov I., Andrianova E., Baranovskiy P.EPMA Journal. Vol. 7. 2016.
DOUBLE-BLIND RANDOMIZED PLACEBOCONTROLLED MULTICENTER CLINICAL TRIAL (PHASE IIA) ON DIINDOLYLMETHANE'S EFFICACY AND SAFETY IN THE TREATMENT OF CIN: IMPLICATIONS FOR CERVICAL CANCER PREVENTION ArticleAshrafian L., Sukhikh G., Kiselev V., Paltsev M., Drukh V., Kuznetsov I., Muyzhnek E., Apolikhina I., Andrianova E.EPMA Journal. Vol. 6. 2015.
SAFETY AND TOLERABILITY OF DIM-BASED THERAPY DESIGNED AS PERSONALIZED APPROACH TO REVERSE PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) ArticlePaltsev M., Kiselev V., Muyzhnek E., Drukh V., Kuznetsov I., Pchelintseva O.EPMA Journal. Vol. 5. 2014.
COMPARATIVE PRECLINICAL PHARMACOKINETICS STUDY OF 3,3′-DIINDOLYLMETHANE FORMULATIONS: IS PERSONALIZED TREATMENT AND TARGETED CHEMOPREVENTION IN THE HORIZON? ArticlePaltsev Mikhail, Kiselev Vsevolod, Muyzhnek Ekaterina, Drukh Vadim, Kuznetsov Igor, Pchelintseva OlgaEPMA Journal. Vol. 4. 2013. P.. 1-8